{"DataElement":{"publicId":"12413869","version":"1","preferredName":"Pharmacokinetics Concentrations Supplemental Qualifiers Dataset Biospecimen Collection Time Collection Period Type","preferredDefinition":"The collection time Period of the biospecimen.","longName":"SUPPPC_QVAL_PCSPCTPT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"12411403","version":"1","preferredName":"Pharmacokinetics Concentrations Supplemental Qualifiers Dataset Biospecimen Collection Time","preferredDefinition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacokinetics concentrations domain.:The time that a biospecimen was collected.","longName":"12411401v1.00:12411402v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"12411401","version":"1","preferredName":"Pharmacokinetics Concentrations Supplemental Qualifiers Dataset","preferredDefinition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacokinetics concentrations domain.","longName":"C147233","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmacokinetics Concentrations Supplemental Qualifiers Dataset","conceptCode":"C147233","definition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacokinetics concentrations domain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2A572CF-8C63-3EF7-E053-731AD00A9721","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"12411402","version":"1","preferredName":"Biospecimen Collection Time","preferredDefinition":"The time that a biospecimen was collected.","longName":"C178869","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biospecimen Collection Time","conceptCode":"C178869","definition":"The time that a biospecimen was collected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2A572CF-8C64-3EF7-E053-731AD00A9721","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2182370","version":"1","preferredName":"Procedures","preferredDefinition":"Tests, examinations, evaluations used to determine a subject's status or response to intervention.  ","longName":"PROCEDURES","context":"CCR","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7049CF8-1252-211C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-01","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-01","modifiedBy":"REEVESD","dateModified":"2004-09-24","changeDescription":"Created initially to support CCR value domain for CTMS. ","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2A572CF-8C65-3EF7-E053-731AD00A9721","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-06-07","changeDescription":null,"administrativeNotes":"06/07/2023- Reviewed and released -MM","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12411448","version":"1","preferredName":"Collection Period Type","preferredDefinition":"The act of gathering things together; having been brought together in one place._An interval of time._Something distinguishable as an identifiable class based on common qualities.","longName":"12411448v1.00","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Induction Cycle 1 Day 22, pre-cabozantinib","valueDescription":null,"ValueMeaning":{"publicId":"12413867","version":"1","preferredName":"Induction Cycle One Day Twenty Two pre-cabozantinib","longName":"12413867v1.00","preferredDefinition":"The act of bringing about something._An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence._The smallest natural number and quantity it denotes: a single entity, unit, or object._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._A natural number greater than twenty-one and less than twenty-three and the quantity that it denotes._Earlier in time or order._An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Induction","conceptCode":"C61367","definition":"The act of bringing about something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"One","conceptCode":"C66832","definition":"The smallest natural number and quantity it denotes: a single entity, unit, or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Twenty Two","conceptCode":"C126884","definition":"A natural number greater than twenty-one and less than twenty-three and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cabozantinib","conceptCode":"C52200","definition":"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2AA7A9E-9ACA-297D-E053-731AD00A6EBD","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2AA7A9E-9ACC-297D-E053-731AD00A6EBD","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-01-19","deletedIndicator":"No"},{"value":"Induction Cycle 2 Day 1, pre-cabozantinib","valueDescription":null,"ValueMeaning":{"publicId":"12413868","version":"1","preferredName":"Induction Cycle Two Day One pre-cabozantinib","longName":"12413868v1.00","preferredDefinition":"The act of bringing about something._An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence._A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._The smallest natural number and quantity it denotes: a single entity, unit, or object._Earlier in time or order._An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Induction","conceptCode":"C61367","definition":"The act of bringing about something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Two","conceptCode":"C66833","definition":"A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"One","conceptCode":"C66832","definition":"The smallest natural number and quantity it denotes: a single entity, unit, or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cabozantinib","conceptCode":"C52200","definition":"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2AA7A9E-9ACB-297D-E053-731AD00A6EBD","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2AA7A9E-9ACD-297D-E053-731AD00A6EBD","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-01-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2182370","version":"1","preferredName":"Procedures","preferredDefinition":"Tests, examinations, evaluations used to determine a subject's status or response to intervention.  ","longName":"PROCEDURES","context":"CCR","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7049CF8-1252-211C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-01","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-01","modifiedBy":"REEVESD","dateModified":"2004-09-24","changeDescription":"Created initially to support CCR value domain for CTMS. ","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12411447","version":"1","preferredName":"Collection Period Type","preferredDefinition":"The act of gathering things together; having been brought together in one place._An interval of time._Something distinguishable as an identifiable class based on common qualities.","longName":"12411447v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Collection","conceptCode":"C25453","definition":"The act of gathering things together; having been brought together in one place.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Period","conceptCode":"C25616","definition":"An interval of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2A6DA2C-FBC1-7EAF-E053-731AD00A7DBE","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2A6DA2C-FBC2-7EAF-E053-731AD00A7DBE","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-06-20","changeDescription":null,"administrativeNotes":"06/20/2023- Released upon review-MM","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Collection Period","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2AA9FCF-7D45-30F9-E053-731AD00A10AA","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-01-19","modifiedBy":"MMADDINENI","dateModified":"2023-06-07","changeDescription":null,"administrativeNotes":"06/07/2023-Reviewed and released-MM","unresolvedIssues":null,"deletedIndicator":"No"}}